Adaptimmune Therapeutics (NASDAQ:ADAP) Presents Promising ADP-A2AFP Phase 1 Study Results In HCC

Adaptimmune Therapeutics plc (NASDAQ:ADAP) recently released data from the Phase 1 ADP-A2AFP SPEAR T-cells study targeting AFP during the International Liver Congress.

The favorable safety profile is shown in HCC patients

The data showed a favorable safety profile in hepatocellular carcinoma patients. One patient demonstrated a complete response out of the four patients doses with more than 5 billion SPEAR T-cells. Adaptimmune Chief Medical Officer Elliot Norry stated that the complete responses were in a patient having advanced liver cancer. Norry stated that the antitumor activity previously reported in other subjects with a favorable safety profile further affirms the ongoing ADP-A2AFP study.

The company is optimistic about the therapy’s potential, and it is committed to delivering ADP-A2AFP to HCC patients. Norry said that for now, the company has reported data from four patients dosed with more than 5 billion cells. More results are expected to be shared going forward as more patients receive treatment in the study’s expansion phase. Also, Norry added that the company is reviewing its translational findings and evaluating ways of improving the therapy as required.

Clinica Universidad de Navarra’s Dr. Bruno Sangro presented data from the expansion phase and Cohort 3 of the ADP-A2AFP phase 1 study at the International Liver Congress. University of London’s Tim Meyer presented more data from Cohort 1 and 2.

Positive results from a study of ADP-A2AFP SPEAR T-cells

The results show that the patient who had a complete response also had sustained serum AFP reduction. However, the patient showed disease progression at week 32 after developing new lesions. So far, nine patients have been treated in the study, with four receiving transduced cells of 5 billion or more. One patient showed complete responses; another had stable diseases, while two showed progressive disease. Fiver patients had previously received treatment in cohort 1 and 2 with 100 million and 1 billion doses of transduced cells with all patients showing enhanced responses of stable disease.

The ADP-A2AFP SPEAR T-cells showed an acceptable safety profile, and there was no T-cell linked hepatotoxicity. Also, there were no protocol-associated dose-limiting toxicities.